Orthocell (ASX:OCC) appointed its first Canadian distributor for its nerve repair product Remplir ahead of an official in-country launch in early October, according to a Tuesday Australian bourse filing.

Approval processes for individual hospitals will be started immediately to facilitate the market entry, per the filing. Exclusive distributorships have been secured for Alberta and British Columbia, and further appointments are expected for other Canadian provinces.

The Canadian market launch will be overseen by the firm's existing in-house US-based marketing and medical education teams. Orthocell received a medical device license from Health Canada for the product in April.

The firm's shares jumped nearly 13% in recent trading on Tuesday.